Clinical trial
Oral Topotecan to Treat Recurrent or Persistent Solid Tumors
NCT00382733 · Accelerated Community Oncology Research Network, Other · Completed
Key facts
| NCT number | NCT00382733 |
|---|---|
| Title | Oral Topotecan to Treat Recurrent or Persistent Solid Tumors |
| Official title | Oral Topotecan, Utilization for a Metronomic Dosing Schedule to Treat Recurrent or Persistent Solid Tumors |
| Lead sponsor | Accelerated Community Oncology Research Network, Other |
| Collaborators | GlaxoSmithKline Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Tumors |
| Intervention type | Drug |
| Interventions | Oral Topotecan |
| Enrollment | 26 |
| Start date | Nov 1, 2006 |
| Primary completion | Mar 1, 2011 |
| Completion | Mar 1, 2011 |
| First posted | Sep 29, 2006 |
| Last update posted | Jul 22, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: